IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 02 2020 - 8:00AM
Business Wire
IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on September
1, 2020, the Company granted non-statutory stock options to
purchase an aggregate of 34,000 shares of the Company’s common
stock to two newly hired, non-executive employees. In addition, on
September 1, 2020 the Company granted a newly hired employee a
grant of 3,000 restricted stock units for shares of the Company’s
common stock. These grants were made pursuant to the Company’s 2019
Inducement Stock Incentive Plan, were approved by the Company’s
compensation committee pursuant to a delegation by the Company’s
board of directors, and were made as a material inducement to each
employee’s acceptance of employment with the Company in accordance
with Nasdaq Listing Rule 5635(c)(4) as a component of his or her
employment compensation.
The stock options have an exercise price of $4.53 per share,
equal to the closing price of IVERIC bio’s common stock on
September 1, 2020. Each stock option has a ten year term and vests
over four years, with 25% of the shares underlying the option
vesting on September 1, 2021 and an additional 2.0833% of the
shares underlying the option vesting at the end of each successive
month thereafter. The restricted stock unit grant vests with
respect to 100% of the shares underlying the grant on September 1,
2021. The vesting of each grant is subject to the employee’s
continued service with the Company through the applicable vesting
date. The inducement grants are subject to the terms and conditions
of award agreements covering the grants and the Company’s 2019
Inducement Stock Incentive Plan.
IVERIC bio
IVERIC bio is a science-driven biopharmaceutical company focused
on the discovery and development of novel treatment options for
retinal diseases with significant unmet medical needs. The Company
is currently developing both therapeutic product candidates for
age-related retinal diseases and gene therapy product candidates
for orphan inherited retinal diseases. Vision is Our Mission. For
more information on the Company, please visit
www.ivericbio.com.
ISEE-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200902005277/en/
Investor / Media: IVERIC bio Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
kathy.galante@ivericbio.com Media: SmithSolve Alex Van Rees,
973-442-1555 ext. 111 alex.vanrees@smithsolve.com
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Aug 2024 to Sep 2024
IVERIC bio (NASDAQ:ISEE)
Historical Stock Chart
From Sep 2023 to Sep 2024